Current oncology最新文献

{"title":"Expression of Keratin-1 Predicts Recurrence and Treatment Response in Advanced Laryngeal Cancer: A Potential Therapeutic Target.","authors":"Eun Kyung Jung, S M Abdus Salam, Hye-Bin Jang, Joo Yeon Koo, Eshrat Jahan, Sun-Ae Kim, Ji Young Lee, Kyung-Hwa Lee, Tae Mi Yoon","doi":"10.3390/curroncol32090520","DOIUrl":"10.3390/curroncol32090520","url":null,"abstract":"<p><p>The survival rate of patients with advanced laryngeal cancer has not substantially improved over time. RNA sequencing analysis identified Keratin-1 (KRT1) as a gene potentially associated with cancer recurrence. This study investigated the association between KRT1 expression and recurrence in advanced laryngeal cancer. RNA sequencing was performed to identify candidate genes associated with recurrence. The effects of KRT1 expression on clinical outcomes were evaluated in patients with laryngeal cancer. Multiple experimental techniques were utilized. RNA sequencing of patient samples demonstrated higher KRT1 gene expression in the recurrence group than in non-recurrent cases. Patients with KRT1-positive immunostaining exhibited trends of worse overall survival (OS) and recurrence-free survival (RFS). In vitro studies showed that KRT1 knockdown suppressed tumor cell invasion, cell migration, and expression of epithelial-mesenchymal transition (EMT)-related genes in human head and neck squamous cell carcinoma (HNSCC) cell lines. KRT1 knockdown enhanced tumor cell apoptosis and exhibited synergistic effects with conventional radiation and chemotherapy treatments. KRT1 may serve as a biomarker for predicting advanced laryngeal cancer recurrence and assist with selecting patients to receive concurrent chemoradiotherapy (CCRT). Further molecular investigations are warranted to determine its effects, but KRT1 has potential as a therapeutic target.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.","authors":"Dan-Thanh Christine Nguyen, Cyril Nader, Karl Bélanger, Sarah Lapointe, Bernard Lemieux, Émilie Lemieux-Blanchard, Jean-Paul Bahary, Laura Masucci, Carole Lambert, David Roberge, Robert Moumdjian, Moujahed Labidi, Romain Cayrol, Marie Florescu","doi":"10.3390/curroncol32090516","DOIUrl":"10.3390/curroncol32090516","url":null,"abstract":"<p><p>Standard systemic treatment has not been established for refractory meningioma. This retrospective study aimed to identify prognostic factors for overall survival and document outcomes of systemic therapies. We reviewed patients with meningioma followed at CHUM hospital between 2006 and 2022. Only patients with progression after first-line treatment were included. Among 750 patients, 107 (14%) experienced progression after first-line treatment. They were divided into two groups: Group 1 (<i>n</i> = 69, 64%) received salvage local treatments, and Group 2 (<i>n</i> = 38, 36%) received additional salvage systemic treatments. The median follow-up time from diagnosis was 7.5 years. 10-year OS was 88.3% (Group 1) vs. 67.2% (Group 2) (<i>p</i> = 0.009). Mean survival after stopping systemic treatment was 8.94 months. Key prognostic factors for poorer survival included age ≥ 65 (HR = 2.82; <i>p</i> = 0.009), WHO grade 2 or 3 (HR = 4.25; <i>p</i> = 0.004), and progression after second-line treatment (HR = 4.77; <i>p</i> = 0.004). Bevacizumab was associated with a mPFS of 12 months and 1-year OS of 64,6%, whereas non-Bevacizumab treatments-including Hydroxyurea, Somatostatin, and Sunitinib-were associated with a mPFS of 7 months and 1-year OS of 52,6%. This study highlights the fatal nature of recurrent meningiomas and the urgent need for systemic treatments that can improve their survival.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy.","authors":"Kathrin Halfter, Michael Staehler, Dieter Hölzel, Alexander Crispin, Anne Schlesinger-Raab","doi":"10.3390/curroncol32090515","DOIUrl":"10.3390/curroncol32090515","url":null,"abstract":"<p><p><b>Background</b>: Significant changes in renal cell carcinoma (RCC) drug treatment and improved access to abdominal imaging have recently been implemented. The impact of these changes on patient characteristics and prognosis remains to be quantified. <b>Methods</b>: A population-based cohort of 210,418 RCC cases from the Centre for Cancer Registry Data (ZfKD) diagnosed in Germany between 2000 and 2019 was analyzed in this observational study. Three time periods of diagnosis were defined, the first (2000-2005) functioning as a control. The remaining were defined according to the introduction of tyrosine kinase targeting drugs (2006-2014) and checkpoint inhibitor drugs (2015-2019). Five-year relative survival (RS) trends for each risk group and metastatic RCC (mRCC) were determined using Poisson regression models. <b>Results</b>: Age at diagnosis and the proportion of low-risk disease increased, while the proportion of mRCC decreased (<i>p</i> < 0.0001). RS improved slightly between the first and last period in low (5-year RS 98.7% vs. 100.9%), intermediate (89.2% vs. 91.9%), and high-risk (76.6% vs. 80.3%), as well as mRCC (28.3% vs. 29.1%). The overall change in prognosis was significant in low (<i>p</i> = 0.0233) and high-risk groups (<i>p</i> = 0.0002), but not in intermediate-risk and mRCC groups. In a multivariate analysis, high-risk ccRCC patients appear to profit from drug treatment advances. <b>Conclusions</b>: Earlier detection has improved prognosis for the majority of RCC patients. Further efforts should be aimed at diagnosing more mRCC patients earlier, when surgical tumor removal remains feasible.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy.","authors":"Ju Young Bae, Dae Yong Park, Soumya Banna, Jiun-Ruey Hu, Amr Saleh, Mamas A Mamas, Robert L McNamara, Michael G Nanna, John F Setaro, Luke K Kim, S Elissa Altin","doi":"10.3390/curroncol32090514","DOIUrl":"10.3390/curroncol32090514","url":null,"abstract":"<p><p><b>Background</b>: Despite the high prevalence of malignant pericardial effusions (MPEs), the differences in mortality between those undergoing pericardiocentesis for MPE versus non-malignancy pericardial effusions (NMPEs) are not well characterized. To address this knowledge gap, we aim to compare clinical outcomes following pericardiocentesis among patients with MPE and NMPE. <b>Methods</b>: A retrospective analysis was conducted on the US National Inpatient Sample (NIS) to identify all hospitalizations during which pericardiocentesis was performed between 1 January 2016 and 31 December 2020 (total <i>n</i> = 174,776,205). This cohort was further stratified based on the presence or absence of malignancy. The primary outcome of interest was in-hospital mortality. Secondary outcomes included discharge disposition (categorized as non-home discharges), length of stay, and total hospitalization costs. <b>Results</b>: A total of 85,125 patients with pericardial effusions undergoing pericardiocentesis were identified. Patients with an MPE (<i>n</i> = 24,740) were younger and more likely to have a history of malnutrition, prior radiation, palliative care treatments, and do-not-resuscitate (DNR) orders compared to those with an NMPE (<i>n</i> = 60,385). Lung cancer was the most common malignancy (40.3%) in patients with an MPE requiring pericardiocentesis. The in-hospital mortality following pericardiocentesis was 11.8% in patients with malignancy and 8.2% in patients without (odds ratio (OR) for mortality 1.50 (95% confidence interval [CI]: 1.34-1.68, <i>p</i> < 0.001). Lung cancer, non-Hodgkin lymphoma, esophageal cancer, ovarian cancer, and leukemia were associated with a significantly increased risk of death during the same admission. Non-home discharge, length of stay, and total hospitalization cost were marginally greater in those with an MPE. <b>Conclusions</b>: In patients undergoing pericardiocentesis, those with an MPE had significantly higher in-hospital mortality compared to those with an NMPE. Additionally, the MPE group had a marginally longer length of stay and incurred higher total hospital costs. Further research is warranted to explore optimal treatment strategies for MPEs, particularly in patients with a limited life expectancy.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for Genitourinary Cancer.","authors":"Natsuo Tomita, Takuya Koie","doi":"10.3390/curroncol32090513","DOIUrl":"10.3390/curroncol32090513","url":null,"abstract":"<p><p>As the second most common cancer in men, prostate cancer was diagnosed in 1 [...].</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib.","authors":"Ahmet Oruç, Mustafa Erol, Özlem Şahin, Melek Karakurt Eryılmaz, Murat Araz, Mehmet Artaç","doi":"10.3390/curroncol32090510","DOIUrl":"10.3390/curroncol32090510","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to determine whether body composition parameters affect progression-free survival (PFS) in patients with hormone receptor positive and HER-2 negative metastatic breast cancer treated with ribociclib as first-line therapy.</p><p><strong>Materials and methods: </strong>It was designed as a single-center, retrospective study; therefore, its generalizability is limited. At the start of treatment, ¹⁸F-FDG PET/CT scans were performed on patients, and subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) volume, SAT and VAT SUV (standardized uptake value) mean, SAT and VAT index, skeletal muscle index (SMI), and skeletal muscle radiodensity (SMD) were calculated at the L3 vertebra level. The albumin-myosteatosis gauge (AMG) was defined as SMD × albumin.</p><p><strong>Results: </strong>The study included 73 participants. Increased SAT and VAT volumes were associated with worse PFS (23.4 vs. 35.5 months, <i>p</i>: 0.015; 25.4 vs. 33.3 months, <i>p</i>: 0.114). However, in the multivariable cox regression analysis for progression free survival (PFS), an increase in SAT volume [HR 4.96; <i>p</i>: 0.038)] and SAT SUV mean [HR 2.99; <i>p</i>: 0.016)] were identified as independent risk factors.</p><p><strong>Conclusions: </strong>It should be noted that in patients treated with ribociclib, increases in SAT volume and SAT SUV mean are independent risk factors for PFS.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Review of Hearing Rehabilitation in Pediatric Oncology: Specific Considerations and Barriers.","authors":"Guillaume Courbon, Laurie Lugnier, Johnnie K Bass, Thomas E Merchant, Thierry Morlet, Celine Richard","doi":"10.3390/curroncol32090509","DOIUrl":"10.3390/curroncol32090509","url":null,"abstract":"<p><p>Childhood cancer treatments, including chemotherapy, radiation therapy, and combined modalities, pose significant risks to auditory function due to their ototoxic effects. Cisplatin, a chemotherapeutic agent commonly used in pediatric oncology, causes dose-dependent irreversible sensorineural hearing loss by damaging the inner ear structures, primarily through the generation of reactive oxygen species and the activation of apoptotic pathways. Radiation therapy exacerbates these effects, contributing to both sensorineural and conductive hearing loss via mechanisms such as vascular injury, inflammation, and fibrosis. The severity of hearing loss is influenced by the treatment timing, the cumulative dose, patient age, genetics, and concurrent therapies. The damaging effects of chemotherapy and radiation extend beyond the cochlea, involving the surrounding temporal bone as well as multiple levels of the auditory pathway. While pediatric patients may be candidates for bone-anchored hearing devices or cochlear implants, the need for serial imaging and the potential for implant-related MRI artifacts can complicate the timing of hearing rehabilitation. Moreover, the impact on the subcortical and cortical auditory structures may further influence the rehabilitation outcomes. This scoping review lays the foundation for future clinical and research efforts focused on the development of comprehensive pediatric guidelines for hearing preservation, monitoring, and rehabilitation, while also fostering multidisciplinary collaboration.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Depression on Mortality in Patients with Pancreatic Cancer: A Systematic Review.","authors":"Matthieu Hein, Christelle Bouchart","doi":"10.3390/curroncol32090511","DOIUrl":"10.3390/curroncol32090511","url":null,"abstract":"<p><p>The literature provides evidence of the negative impact of depression on mortality among cancer patients. Depression is also a common comorbidity in pancreatic cancer (PC). The objective of this systematic review was to provide a state-of-the-art overview of the potential role of depression in the excess mortality observed in patients with PC. Based on PRISMA guidelines, a systematic review (PROSPERO: CRD420251135451) was conducted in August 2025 using the Pubmed-Medline and Scopus database. After assessment by two readers of the 325 identified articles, 8 articles (<i>n</i> = 143,033) published between 1 January 2010 and 15 August 2025 investigating the specific impact of depression (diagnosed by psychiatric interviews, self-report questionnaires, or diagnostic codes) on mortality in patients with PC (diagnosed by clinical diagnosis or diagnostic codes) were included in this systematic literature review. Articles that were not research studies and were written in a language other than English/French were not included. Risk of bias was assessed using the ROBINS-I tool. A narrative synthesis of the results was performed for the potential impact of depression on mortality in patients with PC. The reported prevalence of depression in this population ranged from 7.4% to 51.8% (seven studies, <i>n</i> = 142,983), depending on the studies considered. Most of the included studies (seven studies, <i>n</i> = 141,728) consistently reported an increased risk of mortality associated with depression, regardless of cancer stage or treatment received. However, the scientific quality of these studies was generally low, with a significant risk of bias. These results suggest that better integration of depression management in the care of patients with PC could potentially improve clinical outcomes in this high-risk population.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma: Implications for Cancer Biology and Therapeutic Applications.","authors":"Servando Hernandez Vargas, Solmaz Aghaamiri, Jack T Adams, Tyler M Bateman, Belkacem Acidi, Sukhen C Ghosh, Vahid Khalaj, Ahmed O Kaseb, Hop S Tran Cao, Majid Momeny, Ali Azhdarinia","doi":"10.3390/curroncol32090512","DOIUrl":"10.3390/curroncol32090512","url":null,"abstract":"<p><p>(1) Background: Somatostatin receptor 2 (SSTR2), a G protein-coupled receptor, is overexpressed in multiple malignancies, including hepatocellular carcinoma (HCC). While SSTR2 has traditionally been viewed as an inhibitory receptor involved in suppressing hormone secretion and cell proliferation, emerging evidence suggests a more complex role in cancer biology. However, the functional implications of SSTR2 expression in HCC remain poorly understood. This study aimed to systematically investigate the molecular landscape associated with SSTR2 expression in HCC and evaluate its potential as a therapeutic target. (2) Methods: SSTR2 expression patterns across 22 tumor types were assessed using TNMplot, and its expression in HCC was further validated through The Human Protein Atlas. Integrative analysis of transcriptomic profiles, protein expression data, and somatic copy number alterations was performed using data from The Cancer Genome Atlas (TCGA) to stratify HCC patients by SSTR2 expression levels. Gene Ontology (GO) enrichment analysis was conducted via SRplot to uncover biological processes and signaling pathways associated with SSTR2. Kaplan-Meier survival analyses were performed using GEO datasets to determine the prognostic significance of SSTR2 expression. (3) Results: SSTR2 is moderately expressed in the majority of HCC tumors. Elevated SSTR2 expression correlates with significantly poorer overall and disease-specific survival. High SSTR2 levels are associated with activation of oncogenic signaling cascades related to cell proliferation, epithelial-to-mesenchymal transition (EMT), angiogenesis, and metastasis. Additionally, SSTR2 expression is positively correlated with several receptor tyrosine kinases and oncogenes implicated in HCC progression. (4) Conclusions: Our findings suggest that SSTR2 is not merely a passive biomarker but may contribute to HCC pathogenesis through modulation of oncogenic pathways. These data support the rationale for further development of SSTR2-directed therapeutic strategies to inhibit tumor growth and invasion in HCC patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Molecular Profiling of Colorectal Cancer: A Comprehensive Cohort Study of BRAF-Mutated Cases from a Tertiary Centre.","authors":"Julia Freckelton, Justin Mencel, Iris Levink, Sheela Rao, Charlotte Fribbens, Paula Proszek, Damian Brooks, Xin Liu, David Cunningham, Ian Chau, Naureen Starling","doi":"10.3390/curroncol32090507","DOIUrl":"10.3390/curroncol32090507","url":null,"abstract":"<p><p><b>Introduction:</b> Increasingly, identification of BRAF mutation in colorectal cancer is used to guide management and predict cancer behaviour. There is, however, still significant diversity within this cohort of patients, both in terms of clinical phenotype and treatment outcomes. This may be explained, at least in part, by differences between classes of BRAF mutations and the presence of concomitant mutations. <b>Methods:</b> We present a retrospective cohort study of sequential patients diagnosed with BRAF-mutated (V600 and non-V600) colorectal cancer between 2014 and 2022. Information regarding presentation, treatment outcomes and molecular subtype was identified using the electronic medical record. <b>Results:</b> This study included 406 patients with BRAF-mutated colorectal cancer, 253 (228 ^V600BRAF) of whom had localised disease and 153 (137 ^V600BRAF) with metastatic disease at the time of diagnosis. In patients with localised disease at diagnosis, the ^V600BRAF mutation was associated with older median age (73 vs. 63 years, <i>p</i> = 0.04) and a higher prevalence of right-sided primary (73% vs. 40%, <i>p</i> < 0.01), mismatch repair deficiency (56% vs. 8%, <i>p</i> < 0.01), and faster time to disease relapse (<i>p</i> = 0.006). In the metastatic setting, ^non-V600BRAF mutation was associated with a higher prevalence of KRAS mutation (27% vs. 1%, <i>p</i> < 0.01), NRAS mutation (14% vs. 3%, <i>p</i> = 0.04) and PIK3CA mutation (33% vs. 8%, <i>p</i> = 0.02). Mismatch repair deficiency was more common in patients with ^V600BRAF mutations than in those with ^non-V600BRAF mutations (20% vs. 0%, <i>p</i> = 0.01). The median survival of patients with the ^V600BRAF mutation was 14 months, and 34 months in those with ^non-V600BRAF mutations. Concomitant RNF43 mutation in metastatic disease, was associated with a significantly higher incidence of disease control from combined BRAF and EGFR inhibition, when compared to those without an RNF43 mutation (100% vs. 54%, <i>p</i> = 0.02). <b>Conclusions:</b> Presentation and outcomes of BRAF-mutated colorectal cancer are heterogenous. The type of BRAF mutation, and the presence of concomitant RNF43 mutation, may explain some of the differences in cancer behaviour. Routine reporting of RNF43 mutations would assist clinicians to give more personalised treatment recommendations.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}